Skip to main content

Ophthalmology vs Neurology — Deal Terms Comparison

Ophthalmology Median Upfront
$768M
Total: $3.6B
Neurology Median Upfront
$343M
Total: $3.0B
Ophthalmology Royalties
10.2%-20.4%
Tiered to 24.4%
Neurology Royalties
12.4%-19.8%
Tiered to 23.8%

Market Analysis

Ophthalmology and Neurology represent distinct licensing landscapes with different risk-reward dynamics. Phase 2 ophthalmology deals carry a median total deal value of $3.6B with $768M upfront, compared to $3.0B total value and $343M upfront for neurology. The differences reflect divergent clinical development timelines, regulatory pathways, and addressable market sizes.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

or
Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How do ophthalmology and neurology deal terms compare?
Ophthalmology Phase 2 deals average $3.6B total value ($768M upfront), while Neurology deals average $3.0B ($343M upfront). The differences are driven by addressable market size, clinical development complexity, and regulatory pathway characteristics.
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

or
Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating